Vaxican
Next generation immunotherapeutics
About us
Vaxican is a startup raised by a group of people with academic background.
In 2020 we have been a member of MIT Acceleration Programme and since then we have developed and expanded in two directions.
First, where our mission is to create synergistic immunotherapies that really transform the way we treat some of the most devastating diseases we have faced today, especially in cancer.
The second, under the shield of Vaxican Genomics, where we provide the services in the field of next generation sequencing (Oxford Nanopore Technology official service provider) of full genomes of microorganism and targeted sequencing of human and animal DNA/RNA.
Research & Development
Cancer is leading cause of death worldwide, accounting for nearly 10mln deaths in 2020, or nearly one in six deaths.
Immunotherapies have been used to treat various types of cancer for a decade or more, but it is still the case of the future to cure it. In spite of some remarkable successes and billions of dollars spent on research and development, immunotherapy is used mainly for hopeless cases of stage III and stage IV diseases.
Team
Contact us
office@vaxican.com
ul. Kładki 24
80-822 Gdańsk
Poland